Biotech · Private company · Doylestown, PA, US
Evrys Bio, Inc.
Track this companyFree. Adds Evrys Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cureFiscal year 2026 · $961.8KNIH RePORTER 5R44AI157725-04 · fetched Nov 12, 2026
- A single antiviral to treat multiple opportunistic infectionsFiscal year 2025 · $978.8KNIH RePORTER 5R44AI114079-07 · fetched Nov 12, 2026
- Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cureFiscal year 2025 · $961.8KNIH RePORTER 5R44AI157725-03 · fetched Nov 12, 2026
- Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cureFiscal year 2024 · $961.8KNIH RePORTER 4R44AI157725-02 · fetched Nov 12, 2026
- A single antiviral to treat multiple opportunistic infectionsFiscal year 2024 · $983.9KNIH RePORTER 5R44AI114079-06 · fetched Nov 12, 2026